Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$542.57
+0.4%
$517.06
$356.14
$549.52
$43.64B1.54645,791 shs144,499 shs
Immunomedics, Inc. stock logo
IMMU
Immunomedics
$87.86
$87.41
$8.80
$87.93
$20.31B2.94.01 million shsN/A
IPSEN stock logo
IPSEY
IPSEN
$30.72
-0.6%
$29.57
$25.11
$32.25
$10.30B0.53712 shs2,563 shs
Neogen Corporation stock logo
NEOG
Neogen
$5.64
+2.5%
$5.61
$3.87
$18.58
$1.22B1.773.57 million shs3.18 million shs
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
$32.05
+1.5%
$30.26
$23.77
$49.45
$2.16B0.071.14 million shs446,022 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
+0.33%-0.38%+4.25%+41.59%+13.13%
Immunomedics, Inc. stock logo
IMMU
Immunomedics
0.00%0.00%0.00%0.00%0.00%
IPSEN stock logo
IPSEY
IPSEN
-0.58%+2.37%+3.26%+17.61%+7.49%
Neogen Corporation stock logo
NEOG
Neogen
+4.96%+5.16%-0.36%-2.31%-62.66%
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
+2.43%+4.61%+4.50%+19.49%+5.20%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
3.9214 of 5 stars
1.44.00.03.74.02.51.3
Immunomedics, Inc. stock logo
IMMU
Immunomedics
N/AN/AN/AN/AN/AN/AN/AN/A
IPSEN stock logo
IPSEY
IPSEN
N/AN/AN/AN/AN/AN/AN/AN/A
Neogen Corporation stock logo
NEOG
Neogen
4.0765 of 5 stars
3.34.00.00.02.33.32.5
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
4.4372 of 5 stars
3.22.00.03.82.11.72.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
2.80
Moderate Buy$558.112.83% Upside
Immunomedics, Inc. stock logo
IMMU
Immunomedics
0.00
N/AN/AN/A
IPSEN stock logo
IPSEY
IPSEN
3.00
BuyN/AN/A
Neogen Corporation stock logo
NEOG
Neogen
2.50
Moderate Buy$7.5034.53% Upside
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
2.43
Hold$44.3336.94% Upside

Current Analyst Ratings Breakdown

Latest IDXX, IPSEY, NEOG, IMMU, and QDEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$510.00 ➝ $540.00
7/1/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$625.00
6/30/2025
Neogen Corporation stock logo
NEOG
Neogen
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $10.00
6/11/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$515.00 ➝ $580.00
5/19/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$460.00 ➝ $510.00
5/8/2025
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$45.00 ➝ $29.00
5/8/2025
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$44.00
5/5/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$548.00 ➝ $558.00
4/22/2025
Neogen Corporation stock logo
NEOG
Neogen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$6.40 ➝ $5.00
4/21/2025
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$38.00 ➝ $25.00
4/14/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$450.00 ➝ $420.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.90B11.20$12.52 per share43.35$19.48 per share27.86
Immunomedics, Inc. stock logo
IMMU
Immunomedics
$290K70,028.66N/AN/A$1.38 per share63.67
IPSEN stock logo
IPSEY
IPSEN
$3.87B2.66N/AN/AN/A
Neogen Corporation stock logo
NEOG
Neogen
$906.00M1.34$1.09 per share5.11$14.52 per share0.38
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
$2.78B0.79$37.21 per share0.87$44.38 per share0.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$887.87M$10.8250.1639.973.9322.76%57.35%26.97%8/4/2025 (Confirmed)
Immunomedics, Inc. stock logo
IMMU
Immunomedics
-$357.19M-$1.84N/AN/AN/AN/A-132.40%-51.32%N/A
IPSEN stock logo
IPSEY
IPSEN
$374.30MN/A0.0010.67N/AN/AN/AN/A7/31/2025 (Estimated)
Neogen Corporation stock logo
NEOG
Neogen
-$9.42M-$2.23N/A11.38N/A-53.56%2.69%1.82%7/29/2025 (Estimated)
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
-$2.05B-$4.97N/A10.09N/A-12.07%4.71%2.21%7/30/2025 (Estimated)

Latest IDXX, IPSEY, NEOG, IMMU, and QDEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.28N/AN/AN/A$1.06 billionN/A
7/30/2025Q2 2025
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
$0.0122N/AN/AN/A$612.36 millionN/A
7/29/2025Q4 2025
Neogen Corporation stock logo
NEOG
Neogen
$0.09N/AN/AN/A$222.52 millionN/A
5/7/2025Q1 2025
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
$0.61$0.74+$0.13-$0.19$694.97 million$692.80 million
5/1/2025Q1 2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$2.93$2.96+$0.03$2.96$998.25 million$998.43 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
N/AN/AN/AN/AN/A
Immunomedics, Inc. stock logo
IMMU
Immunomedics
N/AN/AN/AN/AN/A
IPSEN stock logo
IPSEY
IPSEN
$0.260.85%N/AN/AN/A
Neogen Corporation stock logo
NEOG
Neogen
N/AN/AN/AN/AN/A
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
N/AN/AN/AN/AN/A

Latest IDXX, IPSEY, NEOG, IMMU, and QDEL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/3/2025
IPSEN stock logo
IPSEY
IPSEN
$0.28960.97%6/9/20256/10/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.31
1.16
0.81
Immunomedics, Inc. stock logo
IMMU
Immunomedics
N/A
12.84
12.58
IPSEN stock logo
IPSEY
IPSEN
N/A
1.34
1.15
Neogen Corporation stock logo
NEOG
Neogen
0.33
3.91
2.45
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
0.70
1.20
0.66

Institutional Ownership

CompanyInstitutional Ownership
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
87.84%
Immunomedics, Inc. stock logo
IMMU
Immunomedics
88.89%
IPSEN stock logo
IPSEY
IPSEN
N/A
Neogen Corporation stock logo
NEOG
Neogen
96.73%
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
99.00%

Insider Ownership

CompanyInsider Ownership
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.98%
Immunomedics, Inc. stock logo
IMMU
Immunomedics
12.00%
IPSEN stock logo
IPSEY
IPSEN
N/A
Neogen Corporation stock logo
NEOG
Neogen
1.13%
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
0.79%
CompanyEmployeesShares OutstandingFree FloatOptionable
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
11,00080.42 million79.63 millionOptionable
Immunomedics, Inc. stock logo
IMMU
Immunomedics
366231.14 millionN/AOptionable
IPSEN stock logo
IPSEY
IPSEN
5,358335.26 millionN/ANot Optionable
Neogen Corporation stock logo
NEOG
Neogen
2,110217.04 million214.59 millionOptionable
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
6,60067.63 million67.09 millionOptionable

Recent News About These Companies

Best Value Stocks to Buy for July 8th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
IDEXX Laboratories stock logo

IDEXX Laboratories NASDAQ:IDXX

$542.57 +1.93 (+0.36%)
As of 02:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Immunomedics stock logo

Immunomedics NASDAQ:IMMU

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.

IPSEN stock logo

IPSEN OTCMKTS:IPSEY

$30.72 -0.18 (-0.58%)
As of 07/9/2025 02:30 PM Eastern

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Neogen stock logo

Neogen NASDAQ:NEOG

$5.64 +0.14 (+2.45%)
As of 02:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared foods and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

QuidelOrtho stock logo

QuidelOrtho NASDAQ:QDEL

$32.05 +0.48 (+1.52%)
As of 02:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.